JP2004155780A - 生活習慣病改善剤組成物 - Google Patents
生活習慣病改善剤組成物 Download PDFInfo
- Publication number
- JP2004155780A JP2004155780A JP2003356473A JP2003356473A JP2004155780A JP 2004155780 A JP2004155780 A JP 2004155780A JP 2003356473 A JP2003356473 A JP 2003356473A JP 2003356473 A JP2003356473 A JP 2003356473A JP 2004155780 A JP2004155780 A JP 2004155780A
- Authority
- JP
- Japan
- Prior art keywords
- lifestyle
- estrogen
- composition
- yellow
- related disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 239000000262 estrogen Substances 0.000 claims abstract description 26
- 229940011871 estrogen Drugs 0.000 claims abstract description 26
- 208000008589 Obesity Diseases 0.000 claims abstract description 8
- 235000020824 obesity Nutrition 0.000 claims abstract description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 17
- 229960005309 estradiol Drugs 0.000 claims description 16
- 229930182833 estradiol Natural products 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 239000003075 phytoestrogen Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 241000405911 Rehmannia glutinosa Species 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 208000019622 heart disease Diseases 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 15
- 239000000284 extract Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000009806 oophorectomy Methods 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229940010454 licorice Drugs 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 241001629703 Pueraria candollei var. mirifica Species 0.000 description 3
- 235000015724 Trifolium pratense Nutrition 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 235000013526 red clover Nutrition 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000906543 Actaea racemosa Species 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- 241000037831 Polygonatum sibiricum Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 229940089133 vitamin b6 5 mg Drugs 0.000 description 2
- 239000009538 yokuinin Substances 0.000 description 2
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- GXNFPEOUKFOTKY-UHFFFAOYSA-N All-Trans Coenzyme Q6 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O GXNFPEOUKFOTKY-UHFFFAOYSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- KHQJKXHCWOHDQD-HGUWTHONSA-M Cefazolin sodium hydrate Chemical compound O.O.O.O.O.[Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 KHQJKXHCWOHDQD-HGUWTHONSA-M 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- GXNFPEOUKFOTKY-LPHQIWJTSA-N ubiquinone-6 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O GXNFPEOUKFOTKY-LPHQIWJTSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Abstract
【解決手段】エストロゲン及び熟地黄を含有することを特徴とする生活習慣病改善剤組成物。
【選択図】なし
Description
熟地黄 200 mg(500mg)
エストラジオール 0.3 mg
プロゲステロン 1 mg
乳糖 500 mg
トウモロコシデンプン 245 mg
メタケイ酸アルミン酸マグネシウム 32.5 mg
軽質無水ケイ酸 37.5 mg
低置換度ヒドロキシプロピルセルロース 50 mg
ヒドロキシプロピルセルロース 50 mg
上記組成の粉体1116.3gをで湿式で攪拌造粒し、流動層乾燥機で乾燥した。24メッシュの篩で分級し、篩残は粗砕した。これにステアリン酸マグネシウム10gを添加して混合し、打錠用顆粒を得た。この打錠用顆粒を打錠機で打錠し、1錠重量250mgの錠剤を得た。
熟地黄 200 mg(500mg)
イソフラボン 120 mg
タウリン 1500 mg
ユビキノン 30 mg
ビタミンB6 5 mg
ビタミンB12 10 mg
ビタミンC 90 mg
ビタミンE 10 mg
ニコチン酸アミド 20 mg
乳糖 500 mg
トウモロコシデンプン 245 mg
メタケイ酸アルミン酸マグネシウム 32.5 mg
軽質無水ケイ酸 37.5 mg
低置換度ヒドロキシプロピルセルロース 50 mg
ヒドロキシプロピルセルロース 50 mg
上記組成の粉体1450gを湿式で攪拌造粒し、流動層乾燥機で乾燥した。24メッシュの篩で分級し、篩残は粗砕した。これにステアリン酸マグネシウム10gを添加して混合し、打錠用顆粒を得た。この打錠用顆粒を打錠機で打錠し、1錠重量250mgの錠剤を得た。
熟地黄 200 mg(500mg)
茴香 50 mg(500mg)
イソフラボン 120 mg
タウリン 1500 mg
dl−塩化カルニチン 50 mg
ビタミンA 2000 mg
ビタミンB1 20 mg
ビタミンB2 12 mg
ビタミンB6 5 mg
ビタミンB12 10 mg
ビタミンC 90 mg
ビタミンE 10 mg
ニコチン酸アミド 20 mg
ユビキノン 100 mg
乳糖 500 mg
トウモロコシデンプン 245 mg
メタケイ酸アルミン酸マグネシウム 31 mg
軽質無水ケイ酸 37 mg
低置換度ヒドロキシプロピルセルロース 50 mg
ヒドロキシプロピルセルロース 50 mg
上記組成の粉体1700gを湿式で攪拌造粒し、流動層乾燥機で乾燥した。24メッシュの篩で分級し、篩残は粗砕した。これにステアリン酸マグネシウム10gを添加して混合し、打錠用顆粒を得た。この打錠用顆粒を打錠機で打錠し、1錠重量250mgの錠剤を得た。
熟地黄 100 mg(250mg)
レッドクローバー 50 mg(250mg)
プエラリアミリフィカ 25 mg(250mg)
紅麹末 500 mg
ユビキノン 50 mg
ビタミンC 45 mg
ビタミンE 5 mg
乳糖 300 mg
トウモロコシデンプン 150 mg
メタケイ酸アルミン酸マグネシウム 30 mg
軽質無水ケイ酸 30 mg
低置換度ヒドロキシプロピルセルロース 50 mg
ヒドロキシプロピルセルロース 50 mg
上記組成の粉体1385gを湿式で攪拌造粒し、流動層乾燥機で乾燥した。24メッシュの篩で分級し、篩残は粗砕した。これにステアリン酸マグネシウム5g及びタルク10gを添加して混合した。得られた顆粒を400mgずつ1号カプセルに充填し、カプセル剤を得た。
実験材料:エストラジオール、熟地黄エキス
実験動物:Wistar系雌性ラット(10週令、チャールズリバーから購入)
試験方法:卵巣摘出ラットの体重及び血中コレステロール値測定試験
ラットをペントバルビタール麻酔下、背部を切開、卵巣を摘出(以下、OVXという。)した。縫合後、放置し、その3時間後及び24時間後にセファゾリンナトリウム水和物20mg(力価)/kgを皮下投与した。OVX5日後、体重を平均化し、群構成した後、エストラジオール(5%エタノール/オリーブ油に溶解、0.2mL/100g)、熟地黄エキス(0.5%カルボキシルメチルセルロース・ナトリウムに懸濁、0.5mL/100g)を単独あるいは併用にて、1日1回21日間連続経口投与を行った。
疑似手術群に比較し、OVXを施したラットの子宮重量は有意に減少した。これに対してエストラジオールの単独投与では0.03mg/kg以上の投与量において、体重の増加を抑制し(データにはない)、0.01mg/kgの単独投与では効果がなかった。
疑似手術群に比較し、OVXを施したラットの総コレステロール値は有意に増加した。これに対してエストラジオール単独投与では総コレステロールの上昇を用量依存的に抑制し、0.1mg/kg以上の投与量において有意に抑制した。
Claims (5)
- エストロゲン及び熟地黄を含有することを特徴とする生活習慣病改善剤組成物。
- エストロゲン1質量部に対し、熟地黄を原生薬に換算して10質量部以上含有することを特徴とする生活習慣病改善剤組成物。
- エストロゲンが植物性エストロゲンである請求項1又は2記載の生活習慣病改善剤組成物。
- エストロゲンがエストラジオールである請求項1又は2記載の生活習慣病改善剤組成物。
- 生活習慣病が高脂血症又は肥満である請求項1〜4の何れか1項に記載の生活習慣病改善剤組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003356473A JP2004155780A (ja) | 2002-10-16 | 2003-10-16 | 生活習慣病改善剤組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002301406 | 2002-10-16 | ||
JP2003356473A JP2004155780A (ja) | 2002-10-16 | 2003-10-16 | 生活習慣病改善剤組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004155780A true JP2004155780A (ja) | 2004-06-03 |
Family
ID=32827916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003356473A Pending JP2004155780A (ja) | 2002-10-16 | 2003-10-16 | 生活習慣病改善剤組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2004155780A (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007049955A (ja) * | 2005-08-19 | 2007-03-01 | Ota Isan:Kk | 肥満防止用食品 |
EP2739288A4 (en) * | 2011-08-05 | 2015-03-25 | Lipocine Inc | PROGESTERONE-CONTAINING ORAL PHARMACEUTICAL FORMS AND RELEVANT PROCEDURES |
CN104645055A (zh) * | 2015-03-13 | 2015-05-27 | 青岛云天生物技术有限公司 | 一种治疗肥胖症合并高血脂症的中药组合物及其用途 |
US9358298B2 (en) | 2011-07-28 | 2016-06-07 | Lipocine Inc. | 17-hydroxyprogesterone ester containing oral compositions and related methods |
US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
JP2020050603A (ja) * | 2018-09-26 | 2020-04-02 | 株式会社クラブコスメチックス | エストロゲン受容体発現促進剤および細胞増殖促進剤 |
US11590147B2 (en) | 2015-06-22 | 2023-02-28 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0553394A (ja) * | 1990-12-28 | 1993-03-05 | Canon Inc | 固定装置 |
JPH06263647A (ja) * | 1993-03-12 | 1994-09-20 | Lion Corp | 過酸化脂質の抑制剤 |
JPH08198769A (ja) * | 1995-01-23 | 1996-08-06 | Pola Chem Ind Inc | 過剰栄養吸収抑制剤及びそれを含有する組成物 |
JP2004155779A (ja) * | 2002-10-16 | 2004-06-03 | Taisho Pharmaceut Co Ltd | 更年期症の予防・治療用経口組成物 |
-
2003
- 2003-10-16 JP JP2003356473A patent/JP2004155780A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0553394A (ja) * | 1990-12-28 | 1993-03-05 | Canon Inc | 固定装置 |
JPH06263647A (ja) * | 1993-03-12 | 1994-09-20 | Lion Corp | 過酸化脂質の抑制剤 |
JPH08198769A (ja) * | 1995-01-23 | 1996-08-06 | Pola Chem Ind Inc | 過剰栄養吸収抑制剤及びそれを含有する組成物 |
JP2004155779A (ja) * | 2002-10-16 | 2004-06-03 | Taisho Pharmaceut Co Ltd | 更年期症の予防・治療用経口組成物 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007049955A (ja) * | 2005-08-19 | 2007-03-01 | Ota Isan:Kk | 肥満防止用食品 |
US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
US9358298B2 (en) | 2011-07-28 | 2016-06-07 | Lipocine Inc. | 17-hydroxyprogesterone ester containing oral compositions and related methods |
US9358299B2 (en) | 2011-07-28 | 2016-06-07 | Lipocine Inc | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US9364547B2 (en) | 2011-07-28 | 2016-06-14 | Lipocine Inc. | 17-hydroxyprogesterone ester containing oral compositions and related methods |
US9399069B2 (en) | 2011-07-28 | 2016-07-26 | Lipocine Inc. | 17-Hydroxyprogesterone ester containing oral compositions and related methods |
US10022384B2 (en) | 2011-07-28 | 2018-07-17 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US10709716B2 (en) | 2011-07-28 | 2020-07-14 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
US11471470B2 (en) | 2011-07-28 | 2022-10-18 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
EP2739288A4 (en) * | 2011-08-05 | 2015-03-25 | Lipocine Inc | PROGESTERONE-CONTAINING ORAL PHARMACEUTICAL FORMS AND RELEVANT PROCEDURES |
CN104645055A (zh) * | 2015-03-13 | 2015-05-27 | 青岛云天生物技术有限公司 | 一种治疗肥胖症合并高血脂症的中药组合物及其用途 |
US11590147B2 (en) | 2015-06-22 | 2023-02-28 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
JP2020050603A (ja) * | 2018-09-26 | 2020-04-02 | 株式会社クラブコスメチックス | エストロゲン受容体発現促進剤および細胞増殖促進剤 |
JP7274720B2 (ja) | 2018-09-26 | 2023-05-17 | 株式会社クラブコスメチックス | エストロゲン受容体発現促進剤および細胞増殖促進剤 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zeligs | Diet and estrogen status: the cruciferous connection | |
Bolla | Soybean consumption and health benefits | |
US20060193929A1 (en) | Method for treating or preventing symptoms associated with menopause | |
JP4892856B2 (ja) | 女性ホルモンバランス調整剤 | |
JP2004155779A (ja) | 更年期症の予防・治療用経口組成物 | |
WO2021201532A1 (ko) | 해당화 추출물을 유효성분으로 포함하는 여성 폐경기 증후군 예방, 개선 또는 치료용 조성물 | |
CA2370553A1 (en) | Cardiovascular and bone treatment using isoflavones | |
JP2004155780A (ja) | 生活習慣病改善剤組成物 | |
KR101698051B1 (ko) | 로가닌 또는 이의 유도체를 유효성분으로 함유하는 여성 갱년기 증후군 예방, 개선 또는 치료용 조성물 | |
KR102519649B1 (ko) | 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물 | |
Dasler | Observations on odoratism (sweet pea lathyrism) in the rat | |
JPS6299323A (ja) | 高脂血症剤 | |
KR100419121B1 (ko) | 여성 갱년기 증상의 개선 기능을 갖는 생약조성물을함유하는 기능성 식품 | |
JP2004507510A (ja) | ホルモン関連疾病の処置のための、花粉抽出物を含む組成物の使用 | |
JP2010163403A (ja) | イソプラスタン低下剤 | |
KR101895972B1 (ko) | 번행초 추출물을 포함하는 갱년기 장애의 예방 또는 치료용 조성물 | |
JP4892857B2 (ja) | 更年期症の予防又は改善剤 | |
CA2512149C (en) | Film coated tablet comprising an extract of red vine leaves | |
US20040151769A1 (en) | Film coated tablet containing an extract of red vine leaves | |
ES2236487T3 (es) | Formulacion farmaceutica y su uso para preparar un medicamento para el tratamiento de enfermedades cardiovasculares. | |
JP2011148837A (ja) | リパーゼ阻害剤 | |
JP2005206589A (ja) | リパーゼ阻害剤 | |
JP4706174B2 (ja) | α−グルコシダーゼ阻害剤 | |
TW200306196A (en) | Hormone replacement therapy | |
KR100849806B1 (ko) | 팽윤성 식이섬유와 리파제 억제제를 포함하는 비만 억제조성물 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060824 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090529 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100406 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100803 |